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Systematic reviews of the medical literature are key tools in 
comprehensively summarizing data and helping clinicians 
and policy makers to make informed, evidence-based deci-
sions regarding patient care and health policy.
Systematic reviews often contain a meta-analysis, a 
statistical method that synthesizes the available data from 
independent studies in order to answer a specific research 
question. According to the Cochrane Collaboration—an 
international organization dedicated to promoting and man-
aging systematic reviews and evidence-based medicine—
a meta-analysis (i) provides more precise estimates of the 
effects of an intervention than those from individual studies 
alone and (ii) allows for investigation of consistencies and 
differences across studies (Higgins and Green, 2011).
We review the basic methodology behind high-quality 
systematic reviews and meta-analyses, explain the statistical 
methods and analyses involved in meta-analyses, and empha-
size how this methodological tool can be used in the field of 
dermatology.
sTudY desiGn meThOdOlOGY: FOrmulaTinG  
a clinical quesTiOn, eliGiBiliTY criTeria,  
and search sTraTeGY
Guidelines on how to report systematic reviews and meta-
analyses have helped to establish criteria for developing, 
carrying out, and evaluating these studies. The first set of 
guidelines was published in 1999 under the title QUOROM 
(QUality Of Reporting Of Meta-analysis) Statement (Moher 
et al., 1999). In 2009 these guidelines further evolved into 
PRISMA (Preferred Reporting Items for Systematic reviews 
and Meta-Analyses), which established a 27-item checklist to 
aid researchers in planning and reporting studies (http://www.
prisma-statement.org) (Liberati et al., 2009). The PRISMA 
statement is also a useful tool for readers to reference when 
evaluating a systematic review or meta-analysis.
Formulating an appropriate and specific research ques-
tion is key to any study and underpins systematic reviews 
and meta-analyses. A research question should be feasi-
ble, interesting, novel, ethical, and relevant, known as the 
FINER criteria (Thabane et al., 2009). A well-established 
format for structuring research questions is known by the 
acronym PICOT: Population, Intervention, Comparator, 
Outcome, Time-frame (Liberati et al., 2009; Moher et al., 
2009). For example, in the systematic review and meta-
analysis published by Hadley et al. (2006) in the Journal 
of Investigative Dermatology on the use of imiquimod 
for actinic keratosis, the population was patients with 
actinic keratosis (AK), the intervention was use of topical 
imiquimod, the comparator was placebo vehicle cream, 
ADVANTAGES OF SYSTEMATIC REVIEWS 
AND META-ANALYSES
•  A systematic review is a comprehensive summary 
of available data pertaining to a specific question, 
organized through a rigorous design. Such reviews 
often contain a meta-analysis, which is a statistical 
method for synthesizing data from multiple studies.
•  These techniques are used to answer specific 
research questions and help to minimize bias, 
improve precision of intervention estimates, and 
increase the statistical power of identifying a real 
effect. They may also help to settle controversy 
when individual studies show conflicting results 
and can be used to identify research gaps.
LIMITATIONS
•  Limitations include the risk of misleading results if 
individual studies are biased or their reporting is 
not standardized. Although they are often useful for 
summarizing an intervention effect from randomized 
controlled trials, meta-analyses are less effective 
for capturing adverse effects or summarizing 
observational studies.
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PRISMA, authors are encouraged to contact study authors for 
clarification and identification of further studies, and they 
should explicitly announce such contact, as well as specify 
the date last searched (Moher et al., 2009). The search results 
should be presented in a flow diagram that clearly illustrates 
the number of studies included and the reasons for exclu-
sion of studies that met initial search criteria (Figure 1).
After key studies have been identified for inclusion in 
the systematic review, two independent reviewers extract 
data from the studies. These results should be extracted on 
piloted standardized forms.
assessinG risK OF Bias in indiVidual sTudies
Having identified appropriate studies and extracted data 
in duplicate, the author should assess individual studies 
for bias. Both PRISMA and Cochrane caution against the 
use of numerical scales to assess the quality of studies, 
recommending a more descriptive approach of assessed 
methodological components. Studies should be assessed for 
selection bias (appropriate generation of random allocation 
sequence, concealment of this sequence, and intention-to-
treat analyses), performance bias (blinding of participants 
and providers), detection bias (blinding of outcome assess-
ment), attrition bias (loss to follow-up), and reporting bias 
(differences between reported and unreported findings) 
(Liberati et al., 2009; Moher et al., 2009). An excellent 
example of a bias assessment and discussion can be seen 
in the recent systematic review by Nankervis et al. (2012), 
“Prospective Registration and Outcome-Reporting Bias 
in Randomized Controlled Trials of Eczema Treatments: A 
Systematic Review.”
the outcome measures were multiple and included com-
plete clearance of lesions in treatment area, partial clear-
ance, and complete clearance of a particular lesion, and 
the time-frame was number of weeks of treatment needed. 
Structuring a research question by addressing each of these 
elements is independently associated with better reporting 
quality in randomized controlled trials (RCTs) (Rios et al., 
2010) and should also be used in approaching systematic 
reviews and meta-analyses (Higgins and Green, 2011).
A hallmark of the systematic review is prespecified inclu-
sion and exclusion criteria for studies, known as eligibility 
criteria. These criteria stem from the PICOT question above, 
defining the types of participants that will be included and 
the types of interventions to be studied and potentially 
also limiting the type of study design (Higgins and Green, 
2011; Moher et al., 2009). To use the same study example as 
above, inclusion criteria for the systematic review by Hadley 
et al. were randomized, double-blind trials investigating 
imiquimod for AK with efficacy or safety data. Exclusion 
criteria were reviews with clinical information published 
elsewhere, biochemical or immunological studies, abstracts, 
and studies of conditions other than AK.
Once the research question and eligibility criteria have 
been established, a search strategy should be laid out. This 
strategy will specify the electronic databases to be searched, 
as well as the search terms to be used. The Cochrane 
Collaboration recommends searching the electronic data-
bases CENTRAL and MEDLINE as a minimum, together with 
EMBASE, if available. Searches should also include national 
and regional databases, gray literature (such as technical 
reports or working papers from research groups or commit-
tees), relevant journals, conference abstracts, other reviews 
and guidelines, and ongoing studies in trial registries, over 
a specified period of time (Higgins and Green, 2011). As per 
Figure 1.  Flow diagram illustrating the search strategy and inclusion/
exclusion criteria used in a systematic review and/or meta-analysis. 
Originally published with the PRISMA Statement (Liberati et al., 2009).
Figure 2. Forest plot. Used for presenting the results of a meta-analysis 
comparing two different antibiotic combinations for human brucellosis. 
The summary statistic for each study is shown as a square with a horizontal 
line indicating the confidence interval. At the bottom of the graphic, the 
overall intervention effect estimate is represented by a diamond, with the 
center showing the point estimate and the horizontal tips illustrating the 
confidence interval. The significance of each study and the overall estimate 
are highlighted by whether they cross a vertical line of no effect. Originally 
published with the PRISMA Statement (Liberati et al., 2009).
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sTaTisTical meTa-analYsis
Meta-analysis allows data from multiple studies to be sta-
tistically combined. First, a summary measure is decided 
upon and a summary statistic is estimated for each study. 
Next, an overall intervention effect is calculated. Finally, 
to ensure that the results are valid and robust, researchers 
typically test for heterogeneity and publication bias and 
perform sensitivity analyses. Multiple software programs 
are available for meta-analysis; these may vary in terms of 
usability, although most give consistent numerical results 
(Bax et al., 2007).
The first step in data analysis is to decide on a sum-
mary measure and calculate a corresponding summary 
statistic for each study. The choice of a summary measure 
will depend on the clinical question and type of data. For 
example, for dichotomous or “yes-or-no” data (e.g., did the 
patient develop melanoma: yes or no?), the risk ratio, odds 
ratio, absolute risk reduction, and number needed to treat 
all commonly use summary measures. For survival or time-
to-event data (e.g., the number of months until melanoma 
development), the hazard ratio is the best summary mea-
sure. Researchers should choose the measure that is most 
appropriate for their data and that will give a consistent esti-
mate of the treatment effect for the clinical situation (Deeks, 
2002) and then calculate the same measure for each study. 
Each of the common summary statistics listed above can 
be reexpressed in terms of each other; however, when the 
unit of analysis differs among studies, care must be taken 
to avoid bias. For example, summary statistics may vary sig-
nificantly based on the level of randomization (individual 
or group), number of treatment attempts, number of obser-
vations per patient, and whether multiple observations or 
body areas were included per patient.
Once summary statistics have been derived for each study, 
the overall intervention effect can be calculated. This effect 
is the pooled or weighted average of the effects estimated 
from the individual studies. Two commonly used approaches 
for combining data include fixed-effects and random-effects 
models. Fixed-effects models (such as Mantel–Haenszel and 
inverse variance approaches) account for only within-study 
variability. Random-effects models (such as DerSimonian, 
Laird, and Bayesian approaches) account for both within- 
and between-study variability and are generally considered 
more appropriate in settings of greater between-study het-
erogeneity, as described below. A more detailed summary 
of each of these statistical approaches can be found in the 
Cochrane Handbook for Systematic Reviews of Interventions 
(Higgins and Green, 2011).
Results are typically presented in a forest plot (Figure 2), 
which provides a visual representation of the amount of vari-
ation between studies and the pooled estimate (Lewis and 
Clarke, 2001).
Figure 3. Funnel plot. The results of individual studies are plotted against a 
measure of the precision of the data. In this example, the odds ratio is plotted 
on the horizontal axis and the standard error of the natural log of the odds 
ratio—a measure of the precision of the data—is plotted on the vertical axis 
(this is a more precise estimate of statistical power than sample size alone). 
Because larger studies are more precise, most will fall within an area that 
forms a funnel or inverted V. In the presence of publication bias, fewer small 
studies that do not show a significant effect will be published, leading to a 
blank area in the bottom corner of the graph highlighted by the large blue 
circle. Reprinted and modified from Cochrane Handbook for Systematic 
Reviews of Interventions (Higgins and Green, 2011) with permission from 
Wiley. For additional discussion of funnel plots, see the TED video by Ben 
Goldcare on “Battling Bad Science” available at http://www.ted.com/talks/
ben_goldacre_battling_bad_science.html.
Table 1. rating the strength of clinical recommendations
GRADE 
•  Used by the World Health Organization in their guideline development process
•  Classifies strength of recommendations into strong or weak. A strong recommendation means that based on the available evidence, clinicians are 
very certain that the benefits either do or do not outweigh the risks of an intervention
•  Website: http://www.gradeworkinggroup.org/intro.htm
SORT
•  Used by the American Academy of Dermatology
•  Grades strength of recommendation into A, B, and C, with A-level evidence based on consistent, good-quality, patient-oriented evidence, B based on 
inconsistent or limited-quality, patient-oriented evidence, and C based on consensus, usual practice, or opinion
•  Website: http://www.aad.org/education-and-quality-care/clinical-guidelines/guideline-development-process
Abbreviations: GRADE, grading of recommendations assessment, development and evaluation; SORT, strength of recommendation taxonomy.
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The final steps in a meta-analysis are to assess for sources 
of bias and test the consistency of the results. Heterogeneity, 
or whether there is greater variation in the results between 
the studies than would be attributable to chance, may be 
due to differences between the participants, interventions, 
outcomes, study design and funding, or the statistical meth-
ods used. To assess heterogeneity, statistical methods such 
as the χ2 test and I2 test are commonly used. I2 values <40% 
are generally considered low; however, the statistic may be 
imprecise when few studies are being compared. In addition 
to heterogeneity, publication bias may also affect the results. 
Smaller negative studies are less likely to be published, and 
the treatment effect may be overestimated if such studies are 
not included. Funnel plots are often used to assess for pub-
lication bias (Figure 3). Finally, sensitivity analyses may be 
used to gauge the robustness of results, which may involve 
removing certain studies that are considered heterogeneous 
or of lower quality and then repeating the analysis.
limiTaTiOns OF meTa-analYsis
Meta-analyses may be performed for various reasons. 
Combining data from multiple studies may increase the 
power or chance of detecting a real effect, improve precision, 
and help to settle controversy where individual studies show 
conflicting results. Nonetheless, there is the risk that the 
results may be misleading if the individual studies are subject 
to bias, if there is significant heterogeneity among studies, or 
if there is publication or reporting bias that is not addressed 
appropriately. It is important for authors to reference any 
identified sources of heterogeneity, as well as whether there 
are subgroups for which evidence is stronger than for others, 
and then decide whether there is sufficient evidence to draw 
clear conclusions.
summarY and use OF sYsTemaTic reVieWs  
and meTa-analYses
In a busy health-care setting, systematic reviews and meta-
analyses allow a health-care provider or researcher to 
understand available evidence in a synthesized, coherent 
manner (Williams and Dellavalle, 2012). Whether you are 
performing a systematic review and meta-analysis or read-
ing the literature in order to make a health-care or policy 
decision, it is important to understand the methodology 
behind these techniques. Understanding the methods will 
allow you to assess the quality of the systematic review or 
meta-analysis and the strength of the evidence behind it.
Finally, in using results from a systematic review and 
meta-analysis, either in a clinical practice or in a guide-
line development setting, conclusions are drawn, either 
implicitly or explicitly, regarding the strength of recom-
mendations. There has been a recent movement to employ 
a systematic and explicit approach to making these judg-
ments (Ebell et al., 2004; Guyatt et al., 2008). Table 1 
describes two commonly used systems: GRADE and SORT. 
We refer to these scoring systems here because their use is 
increasing and they are of growing importance to informed 
dermatologists; Cochrane reviews now employ GRADE 
methodology in their summary of findings.
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SUPPLEMENTARY MATERIAL
Answers and a PowerPoint slide presentation appropriate for journal club 
or other teaching exercises are available at http://dx.doi.org/10.1038/
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